Mizuho Securities USA’s Inovio Pharmaceuticals INO Stock Holding History

Mizuho Securities USA’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,333	Closed	-$1.16M	–	219
2020 Q3	$1.16M	Buy	+8,333	New	+$1.74M	0.08%	100
2015 Q1	–	Sell	-1,250	Closed	-$138K	–	247
2014 Q4	$138K	Hold	1,250	–	–	0.01%	234
2014 Q3	$148K	Buy	+1,250	New	+$156K	0.02%	151

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mizuho Securities USA's INO Position: Q4 2020 in Review

Mizuho Securities USA sold out of Inovio Pharmaceuticals (INO) in Q4 2020, closing a stake of 8,333 shares — an estimated $1.16M sold.

Mizuho Securities USA first reported a position in INO in Q3 2014 and held it in 3 quarters. The position peaked at $1.16M in Q3 2020. 227 funds tracked by Wall St. Rank hold INO as of Q4 2020.

Mizuho Securities USA reported no remaining Inovio Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Mizuho Securities USA sold 8,333 Inovio Pharmaceuticals shares in Q4 2020, an estimated $1.16M.
Mizuho Securities USA first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 3 quarters.
Mizuho Securities USA's Inovio Pharmaceuticals position peaked at $1.16M in Q3 2020.
227 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2020.

Based on Mizuho Securities USA's 13F filing for Q4 2020, filed 29 Jan 2021.